Research graph
References from A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
The BCL-2 protein family, BH3-mimetics and cancer therapy
10.1038/cdd.2015.50 · 2015 · External reference
BCL-2 inhibition in AML: an unexpected bonus?
10.1182/blood-2018-03-828269 · 2018 · External reference
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia
10.1158/2159-8290.cd-13-0609 · 2014 · External reference
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
10.1038/s41591-018-0233-1 · 2018 · External reference
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
10.3324/haematol.2018.188094 · 2018 · External reference
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
10.1002/ajh.25000 · 2018 · External reference
Known prognostic models fail to predict outcomes for venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia: a single-center retrospective analysis
10.1002/ajh.70034 · 2025 · External reference
Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission
10.1056/nejmoa2004444 · 2020 · External reference
Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies
10.1371/journal.pone.0135520 · 2015 · External reference
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017 · External reference
Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting
10.1016/j.xpro.2020.100248 · 2021 · External reference
Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states
10.1038/s41590-021-01059-0 · 2021 · External reference
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
10.1182/blood.2024024944 · 2024 · External reference
Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia
10.1158/2159-8290.cd-19-0710 · 2020 · External reference
A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia
10.1158/2159-8290.cd-18-0140 · 2018 · External reference
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
10.1038/s43018-020-0103-x · 2020 · External reference
Efficacy and safety of venetoclax plus azacitidine based regimens in the treatment of relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis
10.1007/s00277-025-06643-0 · 2025 · External reference
Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study
10.1080/10428194.2024.2390574 · 2024 · External reference
Venetoclax-azacitidine versus azacitidine for the treatment of primary refractory or first relapsed acute myeloid leukemia. An IPC-DATAML-MSKCC Retrospective Study
10.1002/ajh.27626 · 2025 · External reference
